Longevity & AgingOral GLP-1 Drug Orforglipron Cuts Blood Sugar and Weight in Type 2 Diabetes Trial
A major international trial called ACHIEVE-5 found that orforglipron, a once-daily oral GLP-1 drug, meaningfully improved blood sugar control in adults with type 2 diabetes who weren't responding adequately to basal insulin alone. Patients saw HbA1c drop by up to 1.88 percentage points compared to 0.79 with placebo. Crucially, participants also lost 2.6% to 5.4% of body weight — even as their insulin doses increased by 30–33%, a combination that typically causes weight gain. No increase in dangerous low blood sugar episodes was observed. Gastrointestinal side effects like nausea were the main downside, with up to 9.6% discontinuing the highest dose. The results were presented at the ADA annual meeting and published simultaneously in JAMA.
